474 related articles for article (PubMed ID: 30798598)
1. Intestinal Barrier Function-Non-alcoholic Fatty Liver Disease Interactions and Possible Role of Gut Microbiota.
Cui Y; Wang Q; Chang R; Zhou X; Xu C
J Agric Food Chem; 2019 Mar; 67(10):2754-2762. PubMed ID: 30798598
[TBL] [Abstract][Full Text] [Related]
2. Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation.
Porras D; Nistal E; Martínez-Flórez S; Pisonero-Vaquero S; Olcoz JL; Jover R; González-Gallego J; García-Mediavilla MV; Sánchez-Campos S
Free Radic Biol Med; 2017 Jan; 102():188-202. PubMed ID: 27890642
[TBL] [Abstract][Full Text] [Related]
3. Gut-liver axis and probiotics: their role in non-alcoholic fatty liver disease.
Paolella G; Mandato C; Pierri L; Poeta M; Di Stasi M; Vajro P
World J Gastroenterol; 2014 Nov; 20(42):15518-31. PubMed ID: 25400436
[TBL] [Abstract][Full Text] [Related]
4. Gut-liver axis, nutrition, and non-alcoholic fatty liver disease.
Kirpich IA; Marsano LS; McClain CJ
Clin Biochem; 2015 Sep; 48(13-14):923-30. PubMed ID: 26151226
[TBL] [Abstract][Full Text] [Related]
5. Obesity, fatty liver disease and intestinal microbiota.
Arslan N
World J Gastroenterol; 2014 Nov; 20(44):16452-63. PubMed ID: 25469013
[TBL] [Abstract][Full Text] [Related]
6. Beneficial effects of exercise on gut microbiota functionality and barrier integrity, and gut-liver crosstalk in an
Carbajo-Pescador S; Porras D; García-Mediavilla MV; Martínez-Flórez S; Juarez-Fernández M; Cuevas MJ; Mauriz JL; González-Gallego J; Nistal E; Sánchez-Campos S
Dis Model Mech; 2019 Apr; 12(5):. PubMed ID: 30971408
[TBL] [Abstract][Full Text] [Related]
7. Intestinal hormones, gut microbiota and non-alcoholic fatty liver disease.
Koukias N; Buzzetti E; Tsochatzis EA
Minerva Endocrinol; 2017 Jun; 42(2):184-194. PubMed ID: 27879962
[TBL] [Abstract][Full Text] [Related]
8. Mechanistic and therapeutic advances in non-alcoholic fatty liver disease by targeting the gut microbiota.
Han R; Ma J; Li H
Front Med; 2018 Dec; 12(6):645-657. PubMed ID: 30178233
[TBL] [Abstract][Full Text] [Related]
9. Gut Microbiota-Derived Components and Metabolites in the Progression of Non-Alcoholic Fatty Liver Disease (NAFLD).
Ji Y; Yin Y; Li Z; Zhang W
Nutrients; 2019 Jul; 11(8):. PubMed ID: 31349604
[TBL] [Abstract][Full Text] [Related]
10. Role of gut microbiota and Toll-like receptors in nonalcoholic fatty liver disease.
Miura K; Ohnishi H
World J Gastroenterol; 2014 Jun; 20(23):7381-91. PubMed ID: 24966608
[TBL] [Abstract][Full Text] [Related]
11. Immunoglobulin A and liver diseases.
Inamine T; Schnabl B
J Gastroenterol; 2018 Jun; 53(6):691-700. PubMed ID: 29075899
[TBL] [Abstract][Full Text] [Related]
12. The Metabolic Role of the Microbiome: Implications for NAFLD and the Metabolic Syndrome.
Quigley EM; Abu-Shanab A; Murphy EF; Stanton C; Monsour HP
Semin Liver Dis; 2016 Sep; 36(4):312-316. PubMed ID: 27997970
[TBL] [Abstract][Full Text] [Related]
13. Gut microbiota and non-alcoholic fatty liver disease.
Gkolfakis P; Dimitriadis G; Triantafyllou K
Hepatobiliary Pancreat Dis Int; 2015 Dec; 14(6):572-81. PubMed ID: 26663004
[TBL] [Abstract][Full Text] [Related]
14. Microbiota, Obesity and NAFLD.
Lau LHS; Wong SH
Adv Exp Med Biol; 2018; 1061():111-125. PubMed ID: 29956210
[TBL] [Abstract][Full Text] [Related]
15. Diammonium Glycyrrhizinate Protects against Nonalcoholic Fatty Liver Disease in Mice through Modulation of Gut Microbiota and Restoration of Intestinal Barrier.
Li Y; Liu T; Yan C; Xie R; Guo Z; Wang S; Zhang Y; Li Z; Wang B; Cao H
Mol Pharm; 2018 Sep; 15(9):3860-3870. PubMed ID: 30036479
[TBL] [Abstract][Full Text] [Related]
16. Role of Probiotics in Non-alcoholic Fatty Liver Disease: Does Gut Microbiota Matter?
Xie C; Halegoua-DeMarzio D
Nutrients; 2019 Nov; 11(11):. PubMed ID: 31752378
[TBL] [Abstract][Full Text] [Related]
17. Small metabolites, possible big changes: a microbiota-centered view of non-alcoholic fatty liver disease.
Chu H; Duan Y; Yang L; Schnabl B
Gut; 2019 Feb; 68(2):359-370. PubMed ID: 30171065
[TBL] [Abstract][Full Text] [Related]
18. Crosstalk between PPARs and gut microbiota in NAFLD.
Wu L; Li J; Feng J; Ji J; Yu Q; Li Y; Zheng Y; Dai W; Wu J; Guo C
Biomed Pharmacother; 2021 Apr; 136():111255. PubMed ID: 33485064
[TBL] [Abstract][Full Text] [Related]
19. Non-Alcoholic Fatty Liver Disease and Extra-Hepatic Cancers.
Sanna C; Rosso C; Marietti M; Bugianesi E
Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27187365
[TBL] [Abstract][Full Text] [Related]
20. [Not Available].
Buffet C
Bull Acad Natl Med; 2014 Dec; 198(9):1641-52. PubMed ID: 27356366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
